8:02AM ISIS Pharm to receive $1.25 mln payment as Pfizer (PFE) continues development of EXC 001 (ISIS) 8.92 : Co announced that it will receive a $1.25 mln contingent payment from Pfizer (PFE) triggered by Pfizer's decision to advance EXC 001 into a Phase 2 study. In 2011, Isis received $4.4 mln for its equity ownership of Excaliard from Pfizer's acquisition of Excaliard Pharmaceuticals and, excluding the $1.25 mln, is eligible to receive an additional $8.35 mln in contingent payments upon achievement of various milestones associated with the clinical and commercial progress of EXC 001, also referred to as PF-06473871. Isis also remains eligible to receive milestone and royalty payments under its licensing agreement with Excaliard for EXC 001.
Market Data 
Markets 
AI
